ES2819534T3 - Derivados de pirimidina como moduladores del receptor GLP-1 - Google Patents
Derivados de pirimidina como moduladores del receptor GLP-1 Download PDFInfo
- Publication number
- ES2819534T3 ES2819534T3 ES15745738T ES15745738T ES2819534T3 ES 2819534 T3 ES2819534 T3 ES 2819534T3 ES 15745738 T ES15745738 T ES 15745738T ES 15745738 T ES15745738 T ES 15745738T ES 2819534 T3 ES2819534 T3 ES 2819534T3
- Authority
- ES
- Spain
- Prior art keywords
- crarb
- compound
- heterocyclyl
- alkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C1(C)C(C)(C)*C*(C)*1 Chemical compound C*C1(C)C(C)(C)*C*(C)*1 0.000 description 17
- QDSDLRRNVPQVDP-UHFFFAOYSA-N Bc1cnc(-c2ccc(CC(C(N(C3)CC3C(OC(C)(C)C)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound Bc1cnc(-c2ccc(CC(C(N(C3)CC3C(OC(C)(C)C)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 QDSDLRRNVPQVDP-UHFFFAOYSA-N 0.000 description 1
- MUSZZEUCRDADJX-SFHVURJKSA-N Bc1cnc(-c2ccc(C[C@@H](C(O)=O)NC(OCc3ccccc3)=O)cc2)nc1 Chemical compound Bc1cnc(-c2ccc(C[C@@H](C(O)=O)NC(OCc3ccccc3)=O)cc2)nc1 MUSZZEUCRDADJX-SFHVURJKSA-N 0.000 description 1
- AXQLHEWHNBIVAY-DEOSSOPVSA-N CC(C)(C)OC(C(C1)CN1C([C@H](Cc(cc1)ccc1-c(nc1)ncc1Br)NC(OCc1ccccc1)=O)=O)=O Chemical compound CC(C)(C)OC(C(C1)CN1C([C@H](Cc(cc1)ccc1-c(nc1)ncc1Br)NC(OCc1ccccc1)=O)=O)=O AXQLHEWHNBIVAY-DEOSSOPVSA-N 0.000 description 1
- PHDLURBLEFDLNP-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1C(NC(Cc(cc1)ccc1-c(nc1)ncc1Br)C(O)=O)=O Chemical compound CC(C)(C)c(cc1)ccc1C(NC(Cc(cc1)ccc1-c(nc1)ncc1Br)C(O)=O)=O PHDLURBLEFDLNP-UHFFFAOYSA-N 0.000 description 1
- UURJKUKTUIGKHM-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1C(NCC(Cc(cc1)ccc1-c(nc1)ncc1Br)C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)c(cc1)ccc1C(NCC(Cc(cc1)ccc1-c(nc1)ncc1Br)C(OC(C)(C)C)=O)=O UURJKUKTUIGKHM-UHFFFAOYSA-N 0.000 description 1
- OLLGXVMMXWYYQJ-UHFFFAOYSA-N CC(C)(C)c1ccc(C(NC(Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCC(COC)CC2)C(N(C2)CC2C(O)=O)=O)=O)[s]1 Chemical compound CC(C)(C)c1ccc(C(NC(Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCC(COC)CC2)C(N(C2)CC2C(O)=O)=O)=O)[s]1 OLLGXVMMXWYYQJ-UHFFFAOYSA-N 0.000 description 1
- VWLHJISLSKOCQU-UHFFFAOYSA-N CC(C)CC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CC(C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CC(C)CC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CC(C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 VWLHJISLSKOCQU-UHFFFAOYSA-N 0.000 description 1
- ZJUKCHPSZMOWJG-UHFFFAOYSA-N CCCC(CC1)C(C)CC1C(CC1)CC=C1c1cnc(-c2ccc(CC(C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CCCC(CC1)C(C)CC1C(CC1)CC=C1c1cnc(-c2ccc(CC(C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 ZJUKCHPSZMOWJG-UHFFFAOYSA-N 0.000 description 1
- YKTLBPSLSVXDMJ-QOVHGVMHSA-N CCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(OC(C)(C)C)=O)O)NC(OCN)=O)cc2)nc1 Chemical compound CCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(OC(C)(C)C)=O)O)NC(OCN)=O)cc2)nc1 YKTLBPSLSVXDMJ-QOVHGVMHSA-N 0.000 description 1
- FRNYUJQOKUCXLA-NWZFMULUSA-N CCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(C[C@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(C[C@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 FRNYUJQOKUCXLA-NWZFMULUSA-N 0.000 description 1
- KQBBGGJUEWWHPA-JWBZAIJWSA-N CCCCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CCCCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 KQBBGGJUEWWHPA-JWBZAIJWSA-N 0.000 description 1
- YAATWJQBUXXGKP-KVAOAQCGSA-N CCC[C@H](CC1)CC[C@@H]1C(CC1C)CC=C1c1cnc(-c2ccc(CC(C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CCC[C@H](CC1)CC[C@@H]1C(CC1C)CC=C1c1cnc(-c2ccc(CC(C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 YAATWJQBUXXGKP-KVAOAQCGSA-N 0.000 description 1
- NCSZWTIITPTYAP-YQXQZCHZSA-N CCO[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CCO[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 NCSZWTIITPTYAP-YQXQZCHZSA-N 0.000 description 1
- NCSZWTIITPTYAP-UBNGAXMOSA-N CCO[C@H](CC1)CC[C@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CCO[C@H](CC1)CC[C@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(N(C3)CC3C(O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 NCSZWTIITPTYAP-UBNGAXMOSA-N 0.000 description 1
- PHCUSGVOPXONJH-DPIQJTGUSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(NS(C)(=O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(NS(C)(=O)=O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 PHCUSGVOPXONJH-DPIQJTGUSA-N 0.000 description 1
- BCQYGYRJVPCFSF-OSMGYRLQSA-N C[C@H](C(O)=O)NC(C(Cc(cc1)ccc1-c(nc1)ncc1C1=CC(C)(C)CC(C)(C)C1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O Chemical compound C[C@H](C(O)=O)NC(C(Cc(cc1)ccc1-c(nc1)ncc1C1=CC(C)(C)CC(C)(C)C1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O BCQYGYRJVPCFSF-OSMGYRLQSA-N 0.000 description 1
- GAYNAJMFLFEIIV-KWKDFTITSA-N C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C(C)(C)C)NC(c1ccc(C(C)(C)C)[s]1)=O)=O Chemical compound C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C(C)(C)C)NC(c1ccc(C(C)(C)C)[s]1)=O)=O GAYNAJMFLFEIIV-KWKDFTITSA-N 0.000 description 1
- LFXWJYGEJJABAV-WQYNLJDLSA-N C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C(C)=O)NC(c1ccc(C(C)(C)C)[s]1)=O)=O Chemical compound C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C(C)=O)NC(c1ccc(C(C)(C)C)[s]1)=O)=O LFXWJYGEJJABAV-WQYNLJDLSA-N 0.000 description 1
- RLOBTQPZJNSKHB-COXFATBWSA-N C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C(OC)=O)NC(c1ccc(C(C)(C)C)[s]1)=O)=O Chemical compound C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C(OC)=O)NC(c1ccc(C(C)(C)C)[s]1)=O)=O RLOBTQPZJNSKHB-COXFATBWSA-N 0.000 description 1
- ZMBQYLSDNYTMCR-NLFFAJNJSA-N C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C1=CCC(C)(C)C=C1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O Chemical compound C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C1=CCC(C)(C)C=C1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O ZMBQYLSDNYTMCR-NLFFAJNJSA-N 0.000 description 1
- MPIPGCXVTCQULJ-NLFFAJNJSA-N C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C1=CCC(C)(C)CC1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O Chemical compound C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C1=CCC(C)(C)CC1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O MPIPGCXVTCQULJ-NLFFAJNJSA-N 0.000 description 1
- QTGDZOAMZDXTCI-JPYJTQIMSA-N C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C1=CCCC1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O Chemical compound C[C@H](C(O)=O)NC([C@H](Cc(cc1)ccc1-c(nc1)ncc1C1=CCCC1)NC(c1ccc(C(C)(C)C)[s]1)=O)=O QTGDZOAMZDXTCI-JPYJTQIMSA-N 0.000 description 1
- AOJIUTCRMFFLNS-GBMLZEGMSA-N C[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 Chemical compound C[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(C[C@@H](C(O)=O)NC(c3ccc(C(C)(C)C)[s]3)=O)cc2)nc1 AOJIUTCRMFFLNS-GBMLZEGMSA-N 0.000 description 1
- YAAVOYIOWVDVLH-MRJYIUEKSA-N C[C@H](CC1)CC[C@@H]1C1CC=C(B2OC(C)(C)C(C)(C)O2)CC1 Chemical compound C[C@H](CC1)CC[C@@H]1C1CC=C(B2OC(C)(C)C(C)(C)O2)CC1 YAAVOYIOWVDVLH-MRJYIUEKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028962P | 2014-07-25 | 2014-07-25 | |
| US201462090040P | 2014-12-10 | 2014-12-10 | |
| US201562161650P | 2015-05-14 | 2015-05-14 | |
| PCT/US2015/042114 WO2016015014A1 (en) | 2014-07-25 | 2015-07-24 | Novel glp-1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2819534T3 true ES2819534T3 (es) | 2021-04-16 |
Family
ID=53777037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15745738T Active ES2819534T3 (es) | 2014-07-25 | 2015-07-24 | Derivados de pirimidina como moduladores del receptor GLP-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9474755B2 (enExample) |
| EP (1) | EP3172199B1 (enExample) |
| JP (2) | JP6556237B2 (enExample) |
| KR (1) | KR102564946B1 (enExample) |
| CN (2) | CN107074820B (enExample) |
| AU (1) | AU2015292356B2 (enExample) |
| CA (1) | CA2955836C (enExample) |
| EA (1) | EA032525B1 (enExample) |
| ES (1) | ES2819534T3 (enExample) |
| IL (1) | IL249896B (enExample) |
| MX (1) | MX382502B (enExample) |
| SG (1) | SG11201700364PA (enExample) |
| WO (1) | WO2016015014A1 (enExample) |
| ZA (1) | ZA201700342B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| KR102271179B1 (ko) | 2013-06-11 | 2021-07-01 | 셀진 인터내셔널 Ii 에스에이알엘 | 신규의 glp-1 수용체 조절제 |
| AU2015292356B2 (en) * | 2014-07-25 | 2020-02-06 | Receptos Llc | Novel GLP-1 receptor modulators |
| CA2969944A1 (en) | 2014-12-10 | 2016-06-16 | Celgene International Ii Sarl | Glp-1 receptor modulators |
| ES2901599T3 (es) * | 2016-09-30 | 2022-03-23 | Receptos Llc | Sal de dimetilaminoetanol de un modulador del receptor GLP-1 |
| EP3615524B1 (en) * | 2017-04-28 | 2022-11-09 | Receptos Llc | Novel glp-1 receptor modulators |
| WO2020210582A1 (en) * | 2019-04-11 | 2020-10-15 | University Of The Sciences | Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| CR20230066A (es) | 2020-08-06 | 2023-05-29 | Gasherbrum Bio Inc | Agonistas del glp-1 heterocíclicos |
| CN112121152B (zh) * | 2020-09-25 | 2021-06-22 | 南京大学 | 利司那肽在制备抗肿瘤药物中的应用 |
| CN112898133B (zh) * | 2021-01-27 | 2022-11-15 | 河北迈尔斯通电子材料有限公司 | 一种反式酮类中间体的制备方法 |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4496797A1 (en) | 2022-03-21 | 2025-01-29 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| KR20250113341A (ko) | 2024-01-18 | 2025-07-25 | 주식회사 티에치팜 | 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비만 예방 또는 치료용 약학적 조성물 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1062206B (it) | 1974-02-01 | 1983-09-20 | Rotta Research Lab S P A A S | Derivati della tirosina attivi sulla muscolatura liscia |
| DE2423536A1 (de) | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| EP1629849B2 (en) | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmaceutical compositions comprising exendins and agonists thereof |
| AU8823498A (en) * | 1997-07-31 | 1999-02-22 | American Home Products Corporation | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| US6583139B1 (en) * | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| RU2220950C2 (ru) | 1997-08-22 | 2004-01-10 | Ф.Хоффманн-Ля Рош Аг | N-алканоилфенилаланиновые производные |
| US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| BR9916027A (pt) | 1998-12-07 | 2001-08-28 | Sod Conseils Rech Applic | Análogos de glp-1 |
| AU777564B2 (en) | 1999-01-14 | 2004-10-21 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist formulations and methods of administration thereof |
| HUP0302772A3 (en) | 2000-03-07 | 2007-03-28 | Sanofi Aventis Deutschland | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
| WO2005061466A1 (ja) | 2003-12-22 | 2005-07-07 | Ajinomoto Co., Inc. | 新規フェニルアラニン誘導体 |
| EP1720839A1 (en) * | 2004-02-10 | 2006-11-15 | Janssen Pharmaceutica N.V. | Pyridazinones as antagonists of a4 integrins |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| WO2008112938A2 (en) | 2007-03-13 | 2008-09-18 | New England Medical Center Hospitals, Inc. | Composition and method for the treatment of diseases affected by a peptide receptor |
| WO2008149382A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| WO2009111700A2 (en) * | 2008-03-07 | 2009-09-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| CN102946882B (zh) * | 2010-02-02 | 2016-05-18 | 格斯有限公司 | 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途 |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US8501982B2 (en) | 2010-06-09 | 2013-08-06 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
| TWI523844B (zh) * | 2011-01-26 | 2016-03-01 | 賽諾菲公司 | 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途 |
| DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| RU2634896C2 (ru) | 2011-12-12 | 2017-11-08 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
| KR102271179B1 (ko) * | 2013-06-11 | 2021-07-01 | 셀진 인터내셔널 Ii 에스에이알엘 | 신규의 glp-1 수용체 조절제 |
| AU2015292356B2 (en) * | 2014-07-25 | 2020-02-06 | Receptos Llc | Novel GLP-1 receptor modulators |
-
2015
- 2015-07-24 AU AU2015292356A patent/AU2015292356B2/en not_active Ceased
- 2015-07-24 MX MX2017000972A patent/MX382502B/es unknown
- 2015-07-24 CN CN201580046095.3A patent/CN107074820B/zh not_active Expired - Fee Related
- 2015-07-24 WO PCT/US2015/042114 patent/WO2016015014A1/en not_active Ceased
- 2015-07-24 EP EP15745738.3A patent/EP3172199B1/en active Active
- 2015-07-24 SG SG11201700364PA patent/SG11201700364PA/en unknown
- 2015-07-24 US US14/809,020 patent/US9474755B2/en active Active
- 2015-07-24 CN CN202011261790.0A patent/CN112457301A/zh active Pending
- 2015-07-24 ES ES15745738T patent/ES2819534T3/es active Active
- 2015-07-24 CA CA2955836A patent/CA2955836C/en active Active
- 2015-07-24 KR KR1020177003172A patent/KR102564946B1/ko active Active
- 2015-07-24 EA EA201790254A patent/EA032525B1/ru not_active IP Right Cessation
- 2015-07-24 JP JP2017525324A patent/JP6556237B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-13 US US15/263,637 patent/US9839664B2/en active Active
-
2017
- 2017-01-02 IL IL249896A patent/IL249896B/en active IP Right Grant
- 2017-01-16 ZA ZA2017/00342A patent/ZA201700342B/en unknown
-
2019
- 2019-06-10 JP JP2019107866A patent/JP2019142984A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170216392A1 (en) | 2017-08-03 |
| IL249896B (en) | 2021-02-28 |
| CA2955836A1 (en) | 2016-01-28 |
| AU2015292356A1 (en) | 2017-02-02 |
| JP2019142984A (ja) | 2019-08-29 |
| ZA201700342B (en) | 2018-12-19 |
| CN107074820B (zh) | 2021-05-18 |
| WO2016015014A1 (en) | 2016-01-28 |
| MX382502B (es) | 2025-03-13 |
| EP3172199A1 (en) | 2017-05-31 |
| CN112457301A (zh) | 2021-03-09 |
| KR102564946B1 (ko) | 2023-08-08 |
| IL249896A0 (en) | 2017-03-30 |
| US20160038487A1 (en) | 2016-02-11 |
| MX2017000972A (es) | 2017-07-27 |
| US9474755B2 (en) | 2016-10-25 |
| JP6556237B2 (ja) | 2019-08-07 |
| US9839664B2 (en) | 2017-12-12 |
| CA2955836C (en) | 2023-02-14 |
| AU2015292356B2 (en) | 2020-02-06 |
| JP2017526734A (ja) | 2017-09-14 |
| EA201790254A1 (ru) | 2017-07-31 |
| SG11201700364PA (en) | 2017-02-27 |
| EA032525B1 (ru) | 2019-06-28 |
| CN107074820A (zh) | 2017-08-18 |
| KR20170040233A (ko) | 2017-04-12 |
| EP3172199B1 (en) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2819534T3 (es) | Derivados de pirimidina como moduladores del receptor GLP-1 | |
| ES2836973T3 (es) | Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes | |
| ES2864349T3 (es) | Nuevos moduladores del receptor GLP-1 | |
| ES2844573T3 (es) | Moduladores del receptor de GLP-1 | |
| EP3615524B1 (en) | Novel glp-1 receptor modulators | |
| HK40042919A (en) | Novel glp-1 receptor modulators | |
| NZ715006B2 (en) | Novel glp-1 receptor modulators | |
| NZ626122B2 (en) | Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes | |
| HK1202864B (en) | Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes |